Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 9/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.42 |
| ▸ | TFPI | P10646 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655307 | 0.92 | EGFR (0.47) | EGFRPTPN1NMT2NMT1BACE1 | |
| SCHEMBL29695557 | 0.88 | NMT1 (0.47) | EGFRNMT2NMT1 | |
| SCHEMBL29462922 | 0.87 | MME (0.43) | EGFRPTPN1NMT2NMT1BACE1 | |
| SCHEMBL17099905 | 0.86 | FOLH1 (0.50) | PTPN1NMT2NMT1BACE1BACE2 | |
| SCHEMBL17099904 | 0.86 | FOLH1 (0.50) | PTPN1NMT2NMT1BACE1BACE2 | |
| SCHEMBL30432578 | 0.86 | EGFR (0.46) | EGFRPTPN1NMT2NMT1BACE1 | |
| SCHEMBL31672189 | 0.85 | FOLH1 (0.50) | EGFRPTPN1BACE1BACE2CTSD | |
| SCHEMBL31672191 | 0.85 | FOLH1 (0.50) | EGFRPTPN1BACE1BACE2CTSD | |
| SCHEMBL24049252 | 0.85 | NMT1 (0.48) | EGFRNMT2NMT1 | |
| SCHEMBL30905707 | 0.85 | GRIN2D (0.46) | EGFRNMT2NMT1BACE1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | EGFR 4124/4885PTPN1 3282/4885NMT2 1105/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | EGFR 4124/4885PTPN1 3282/4885NMT2 1105/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | EGFR 4124/4885PTPN1 3282/4885NMT2 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.